Ghasemi, Ali
Martinez-Usatorre, Amaia http://orcid.org/0000-0002-3416-1529
Li, Luqing
Hicham, Mehdi http://orcid.org/0000-0002-9979-4757
Guichard, Alan http://orcid.org/0000-0001-8623-9570
Marcone, Rachel
Fournier, Nadine http://orcid.org/0000-0002-9347-7929
Torchia, Bruno
Martinez Bedoya, Darel http://orcid.org/0000-0002-1603-5801
Davanture, Suzel
Fernández-Vaquero, Mirian
Fan, Chaofan
Janzen, Jakob
Mohammadzadeh, Yahya
Genolet, Raphael
Mansouri, Nahal
Wenes, Mathias http://orcid.org/0000-0001-8478-8592
Migliorini, Denis http://orcid.org/0000-0003-0151-3222
Heikenwalder, Mathias http://orcid.org/0000-0002-3135-2274
De Palma, Michele http://orcid.org/0000-0001-9128-5459
Article History
Received: 17 March 2023
Accepted: 11 October 2023
First Online: 23 November 2023
Competing interests
: M.D.P. has received sponsored research grants from EVIR Therapeutics, Hoffmann La-Roche and Deciphera Pharmaceuticals, serves on the Scientific Advisory Boards of EVIR Therapeutics, Montis Biosciences, Macomics, Deciphera Pharmaceuticals, Light Chain Bioscience/Novimmune and Genenta, and is an inventor on patents on engineered DCs filed by EPFL. D.M. is a consultant for Limula and MPC Therapeutics, scientific co-founder of Cellula Therapeutics and is an inventor on patents related to CAR-T cell therapy filed by the University of Pennsylvania, Istituto Oncologico della Svizzera Italiana (IOSI) and the University of Geneva. The other authors declare no conflict of interest.